All Brands Owned by Eli Lilly and Company
Eli Lilly and Company owns 2 brands in our database. Browse the complete portfolio of Eli Lilly and Company subsidiaries and brands across various industries.
Company Type
public
Headquarters
Indianapolis, Indiana, USA
Brand Portfolio
2 brands
Stock
NYSE: LLY
Filter by Category
Complete Brand Portfolio
Mounjaro
Owned by Eli Lilly and Company
Pharmaceutical brand of tirzepatide injection for type 2 diabetes treatment, owned by Eli Lilly and Company.
Zepbound
Owned by Eli Lilly and Company
Prescription weight loss medication brand owned by Eli Lilly, containing tirzepatide as the active ingredient.
About Eli Lilly and Company
What does Eli Lilly make?
Eli Lilly makes prescription pharmaceuticals across several therapeutic areas. Its most important products are Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for obesity), which are dual GIP/GLP-1 receptor agonists. The company also makes Verzenio (breast cancer), Trulicity (diabetes), Taltz (psoriasis), Humalog (insulin), and Emgality (migraine).
Is Eli Lilly publicly traded?
Yes, Eli Lilly and Company is listed on NYSE under ticker LLY. Major institutional shareholders include Vanguard Group, BlackRock, and State Street.
Who founded Eli Lilly?
Eli Lilly was founded in 1876 in Indianapolis, Indiana by Colonel Eli Lilly, a Civil War veteran and pharmacist. The company made its first major breakthrough in 1923 when it produced commercial quantities of insulin.
Where is Eli Lilly headquartered?
Eli Lilly is headquartered in Indianapolis, Indiana, USA, where the company was founded in 1876. The company operates research and development centers, manufacturing facilities, and commercial operations in more than 120 countries.
What is Mounjaro and Zepbound?
Mounjaro and Zepbound both contain tirzepatide, a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. Mounjaro is approved for type 2 diabetes, while Zepbound is approved for obesity. Tirzepatide has demonstrated superior efficacy to existing GLP-1 drugs in clinical trials, with patients losing an average of approximately 20% of their body weight in obesity trials.
Who owns Eli Lilly?
Eli Lilly and Company is publicly traded on NYSE with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. David Ricks serves as Chairman and CEO.
Stock Information
Competitors to Eli Lilly and Company
No competing brands found in the same categories. This could be because Eli Lilly and Companyoperates in unique market segments or we're still building our competitor database.
Eli Lilly and Company Brand Portfolio Overview
Eli Lilly and Company maintains a diverse portfolio of 2 brands across multiple industries. This comprehensive brand portfolio demonstrates the company's market presence and strategic business units.
Brand Portfolio by Industry:
- Healthcare & Pharmaceuticals: 2 brands
For consumers and researchers interested in corporate ownership structures, understanding which brands are owned by Eli Lilly and Companyprovides valuable insights into market dynamics, product relationships, and corporate strategy.
Explore More
Jobs at Eli Lilly and Company
Latest News About Eli Lilly and Company
Articles About Eli Lilly and Company
View more articles
Pharmaceutical Brand Ownership: A Complete Guide
Who makes your medications? Discover which corporations own the biggest pharmaceutical brands, from Ozempic to Tylenol, and how pharma M&A affects you.
Monthly IPO Roundup: July 2026 — June's Biggest Listings
June 2026 was the most historic IPO month in market history: SpaceX priced at $135 per share on June 12, raising $75 billion in the largest IPO ever. Quantinuum raised $1.68B, INNIO priced a $2.8B deal, and Bending Spoons filed for a $20B Nasdaq listing. Full recap.
Monthly M&A Roundup: June 2026 Brand Ownership Changes
June 2026's biggest brand ownership moves: Berkshire Hathaway agreed to buy Taylor Morrison for $6.8B, GSK struck a $10.6B deal for Nuvalent, CRH acquired Arcosa for $8.5B, and Qualcomm agreed to buy AI startup Modular for $3.92B. Full breakdown of every major deal.